Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2018

16.05.2018 | Topic Review

Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature

verfasst von: Victor M. Lu, Kevin Phan, Julia X. M. Yin, Kerrie L. McDonald

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

There are many potential biomarkers in glioblastoma (GBM), and meta-analyses represent the highest level of evidence when inferring their prognostic significance. It is possible however, that inherent design properties of the studies included in these meta-analyses may affect the pooled hazard ratio (HR) of the meta-analyses. This meta-epidemiological study aims to investigate the potential bias of three study-level properties in meta-analyses of GBM biomarkers currently published in the literature.

Methods

Seven electronic databases from inception to December 2017 were searched for meta-analyses evaluating different GBM biomarkers, which were screened against specific criteria. Study-level data were extracted from each meta-analysis, and analyzed using logistic regression to yield the ratio of HR (RHR) summary statistic.

Results

Nine meta-analyses investigating different GBM biomarkers were included. Of all the meta-analyses, the HRs of two studies were significantly underestimated by older studies; they investigated biomarkers IDH1 (RHR = 1.145; p = 0.017) and CD133 (RHR = 0.850; p = 0.013). Study-level size and design showed non-significant trends towards affecting the overall HR in all included meta-analyses.

Conclusions

This meta-epidemiological study demonstrated that study-level year can already significantly affect the pooled HR of GBM biomarkers reported by meta-analyses. It is possible that in the future, more study-level properties will exert significant effect. In terms of future GBM biomarker meta-analyses, special consideration of bias should be given to these study-level properties as potential sources of effect on the prognostic pooled HR.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Savovic J, Harris RJ, Wood L, Beynon R, Altman D, Als-Nielsen B, Balk EM, Deeks J, Gluud LL, Gluud C, Ioannidis JP, Juni P, Moher D, Pildal J, Schulz KF, Sterne JA (2010) Development of a combined database for meta-epidemiological research. Res Synth Methods 1(3–4):212–225. https://doi.org/10.1002/jrsm.18 CrossRefPubMed Savovic J, Harris RJ, Wood L, Beynon R, Altman D, Als-Nielsen B, Balk EM, Deeks J, Gluud LL, Gluud C, Ioannidis JP, Juni P, Moher D, Pildal J, Schulz KF, Sterne JA (2010) Development of a combined database for meta-epidemiological research. Res Synth Methods 1(3–4):212–225. https://​doi.​org/​10.​1002/​jrsm.​18 CrossRefPubMed
6.
Zurück zum Zitat Thuy MN, Kam JK, Lee GC, Tao PL, Ling DQ, Cheng M, Goh SK, Papachristos AJ, Shukla L, Wall KL, Smoll NR, Jones JJ, Gikenye N, Soh B, Moffat B, Johnson N, Drummond KJ (2015) A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 22(5):785–799CrossRefPubMed Thuy MN, Kam JK, Lee GC, Tao PL, Ling DQ, Cheng M, Goh SK, Papachristos AJ, Shukla L, Wall KL, Smoll NR, Jones JJ, Gikenye N, Soh B, Moffat B, Johnson N, Drummond KJ (2015) A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 22(5):785–799CrossRefPubMed
9.
Zurück zum Zitat Oxman AD, Guyatt GH, Singer J, Goldsmith CH, Hutchison BG, Milner RA, Streiner DL (1991) Agreement among reviewers of review articles. J Clin Epidemiol 44(1):91–98CrossRefPubMed Oxman AD, Guyatt GH, Singer J, Goldsmith CH, Hutchison BG, Milner RA, Streiner DL (1991) Agreement among reviewers of review articles. J Clin Epidemiol 44(1):91–98CrossRefPubMed
10.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controll Clin Trials 7(3):177–188CrossRef DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controll Clin Trials 7(3):177–188CrossRef
11.
Zurück zum Zitat Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K, Avan A (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233(1):378–386CrossRefPubMed Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K, Avan A (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233(1):378–386CrossRefPubMed
12.
Zurück zum Zitat Chen JR, Xu HZ, Yao Y, Qin ZY (2015) Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis. Acta Neurol Scand 132(5):310–322CrossRefPubMed Chen JR, Xu HZ, Yao Y, Qin ZY (2015) Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis. Acta Neurol Scand 132(5):310–322CrossRefPubMed
13.
Zurück zum Zitat Dai Y, Ning X, Han G, Li W (2016) Assessment of the association between isocitrate dehydrogenase 1 mutation and mortality risk of glioblastoma patients. Mol Neurobiol 53(3):1501–1508CrossRefPubMed Dai Y, Ning X, Han G, Li W (2016) Assessment of the association between isocitrate dehydrogenase 1 mutation and mortality risk of glioblastoma patients. Mol Neurobiol 53(3):1501–1508CrossRefPubMed
18.
Zurück zum Zitat Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M (2016) TERT mutation in glioma: frequency, prognosis and risk. J Clin Neurosci 26:57–62CrossRefPubMed Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M (2016) TERT mutation in glioma: frequency, prognosis and risk. J Clin Neurosci 26:57–62CrossRefPubMed
19.
Zurück zum Zitat Zhang W, Chen H, Lv S, Yang H (2016) High CD133 expression is associated with worse prognosis in patients with glioblastoma. Mol Neurobiol 53(4):2354–2360CrossRefPubMed Zhang W, Chen H, Lv S, Yang H (2016) High CD133 expression is associated with worse prognosis in patients with glioblastoma. Mol Neurobiol 53(4):2354–2360CrossRefPubMed
20.
Zurück zum Zitat Chen JR, Yao Y, Xu HZ, Qin ZY (2016) Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine 95(9):e2583CrossRefPubMedPubMedCentral Chen JR, Yao Y, Xu HZ, Qin ZY (2016) Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine 95(9):e2583CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Louis D, Ohgak H, Wiestler O, Cavenee W (2016) World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon Louis D, Ohgak H, Wiestler O, Cavenee W (2016) World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon
24.
Zurück zum Zitat Carmignani M, Volpe AR, Aldea M, Soritau O, Irimie A, Florian IS, Tomuleasa C, Baritchii A, Petrushev B, Crisan G, Valle G (2014) Glioblastoma stem cells: a new target for metformin and arsenic trioxide. J Biol Regul Homeost Agents 28(1):1–15PubMed Carmignani M, Volpe AR, Aldea M, Soritau O, Irimie A, Florian IS, Tomuleasa C, Baritchii A, Petrushev B, Crisan G, Valle G (2014) Glioblastoma stem cells: a new target for metformin and arsenic trioxide. J Biol Regul Homeost Agents 28(1):1–15PubMed
27.
Zurück zum Zitat Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. https://doi.org/10.1136/bmj.d4002 PubMedCentralCrossRefPubMed Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. https://​doi.​org/​10.​1136/​bmj.​d4002 PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://​doi.​org/​10.​1056/​NEJMoa043330 CrossRefPubMed
Metadaten
Titel
Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature
verfasst von
Victor M. Lu
Kevin Phan
Julia X. M. Yin
Kerrie L. McDonald
Publikationsdatum
16.05.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2897-2

Weitere Artikel der Ausgabe 2/2018

Journal of Neuro-Oncology 2/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.